Ulrik Lassen, MD, PhD, discusses the updated response findings with larotrectinib in TRK+ cancers.
Ulrik Lassen, MD, PhD
Advertisement
Articles by Ulrik Lassen, MD, PhD
Advertisement
Latest Updated Articles
Updated Response Findings With Larotrectinib in TRK+ CancersPublished: October 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
